Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Børset, M.
Right arrow Articles by Sanderson, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Børset, M.
Right arrow Articles by Sanderson, R. D.
Related Collections
Right arrow Neoplasia
Right arrow Cell Adhesion and Motility
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 October 2000, Vol. 96, No. 7, pp. 2528-2536

NEOPLASIA

Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins

Magne Børset, Øyvind Hjertner, Shmuel Yaccoby, Joshua Epstein, and Ralph D. Sanderson

From Arkansas Cancer Research Center and Departments of Pathology and Anatomy, University of Arkansas for Medical Sciences, Little Rock, AR; and Institute of Cancer Research and Molecular Biology, Norwegian University of Science and Technology, Trondheim, Norway.

Syndecan-1 (CD138) is a heparan sulfate-bearing proteoglycan present on the surface of myeloma cells where it mediates myeloma cell-cell and cell-extracellular matrix adhesion. In this study, we examined myeloma cell lines for cell membrane localization of syndecan-1. On some cells we note a striking localization of syndecan-1 to a single small membrane protrusion, with the remainder of the cell surface being mostly negative for syndecan-1. Examination of cell morphology reveals that a proportion of cells from myeloma cell lines, as well as primary myeloma cells, are polarized, with a uropod on one end and lamellipodia on the other end. On these polarized cells, syndecan-1 is specifically targeted to the uropod, but in contrast, on nonpolarized cells syndecan-1 is evenly distributed over the entire cell surface. In addition to syndecan-1, several other cell surface molecules localize specifically to the uropod, including CD44 and CD54. Functional assays reveal that myeloma cell lines with a high proportion of polarized cells have a much higher migratory potential than cell lines with few polarized cells. Moreover, the uropod is the cell pole preferentially involved in aggregation of myeloma cells and in adhesion of myeloma cells to osteoblast-like cells. When polarized myeloma cells are incubated with heparin-binding proteins, like hepatocyte growth factor or osteoprotegerin, they concentrate in the uropod. These data indicate that syndecan-1 is targeted to the uropod of polarized myeloma cells and that this targeting plays a role in promoting cell-cell adhesion and may also regulate the biological activity of heparin-binding cytokines.

© 2000 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
H. Ikeda, T. Hideshima, M. Fulciniti, R. J. Lutz, H. Yasui, Y. Okawa, T. Kiziltepe, S. Vallet, S. Pozzi, L. Santo, et al.
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
Clin. Cancer Res., June 15, 2009; 15(12): 4028 - 4037.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Lamoureux, G. Picarda, L. Garrigue-Antar, M. Baud'huin, V. Trichet, A. Vidal, E. Miot-Noirault, B. Pitard, D. Heymann, and F. Redini
Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma
Cancer Res., January 15, 2009; 69(2): 526 - 536.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Purushothaman, L. Chen, Y. Yang, and R. D. Sanderson
Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in Myeloma
J. Biol. Chem., November 21, 2008; 283(47): 32628 - 32636.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y.-T. Tai, M. Dillon, W. Song, M. Leiba, X.-F. Li, P. Burger, A. I. Lee, K. Podar, T. Hideshima, A. G. Rice, et al.
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
Blood, August 15, 2008; 112(4): 1329 - 1337.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Yang, V. MacLeod, Y. Dai, Y. Khotskaya-Sample, Z. Shriver, G. Venkataraman, R. Sasisekharan, A. Naggi, G. Torri, B. Casu, et al.
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
Blood, September 15, 2007; 110(6): 2041 - 2048.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Yang, V. MacLeod, H.-Q. Miao, A. Theus, F. Zhan, J. D. Shaughnessy Jr., J. Sawyer, J.-P. Li, E. Zcharia, I. Vlodavsky, et al.
Heparanase Enhances Syndecan-1 Shedding: A NOVEL MECHANISM FOR STIMULATION OF TUMOR GROWTH AND METASTASIS
J. Biol. Chem., May 4, 2007; 282(18): 13326 - 13333.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. N. Pearse
Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling.
Clin. Cancer Res., October 15, 2006; 12(20): 6274s - 6278s.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Nadav, B.-Z. Katz, S. Baron, N. Cohen, E. Naparstek, and B. Geiger
The Generation and Regulation of Functional Diversity of Malignant Plasma Cells.
Cancer Res., September 1, 2006; 66(17): 8608 - 8616.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Dai, Y. Yang, V. MacLeod, X. Yue, A. C. Rapraeger, Z. Shriver, G. Venkataraman, R. Sasisekharan, and R. D. Sanderson
HSulf-1 and HSulf-2 Are Potent Inhibitors of Myeloma Tumor Growth in Vivo
J. Biol. Chem., December 2, 2005; 280(48): 40066 - 40073.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Kelly, L. J. Suva, Y. Huang, V. MacLeod, H.-Q. Miao, R. C. Walker, and R. D. Sanderson
Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases
Cancer Res., July 1, 2005; 65(13): 5778 - 5784.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. A. Mosheimer, N. C. Kaneider, C. Feistritzer, A. M. Djanani, D. H. Sturn, J. R. Patsch, and C. J. Wiedermann
Syndecan-1 Is Involved in Osteoprotegerin-Induced Chemotaxis in Human Peripheral Blood Monocytes
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2964 - 2971.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Vincent, D. K. Jin, M. A. Karajannis, K. Shido, A. T. Hooper, W. K. Rashbaum, B. Pytowski, Y. Wu, D. J. Hicklin, Z. Zhu, et al.
Fetal Stromal-Dependent Paracrine and Intracrine Vascular Endothelial Growth Factor-A/Vascular Endothelial Growth Factor Receptor-1 Signaling Promotes Proliferation and Motility of Human Primary Myeloma Cells
Cancer Res., April 15, 2005; 65(8): 3185 - 3192.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
E. Tkachenko, J. M. Rhodes, and M. Simons
Syndecans: New Kids on the Signaling Block
Circ. Res., March 18, 2005; 96(5): 488 - 500.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. K. Langford, Y. Yang, T. Kieber-Emmons, and R. D. Sanderson
Identification of an Invasion Regulatory Domain within the Core Protein of Syndecan-1
J. Biol. Chem., February 4, 2005; 280(5): 3467 - 3473.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Yang, V. MacLeod, M. Bendre, Y. Huang, A. M. Theus, H.-Q. Miao, P. Kussie, S. Yaccoby, J. Epstein, L. J. Suva, et al.
Heparanase promotes the spontaneous metastasis of myeloma cells to bone
Blood, February 1, 2005; 105(3): 1303 - 1309.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Hov, R. U. Holt, T. B. Ro, U.-M. Fagerli, H. Hjorth-Hansen, V. Baykov, J. G. Christensen, A. Waage, A. Sundan, and M. Borset
A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells
Clin. Cancer Res., October 1, 2004; 10(19): 6686 - 6694.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Podar, L. P. Catley, Y.-T. Tai, R. Shringarpure, P. Carvalho, T. Hayashi, R. Burger, R. L. Schlossman, P. G. Richardson, L. N. Pandite, et al.
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment
Blood, May 1, 2004; 103(9): 3474 - 3479.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. C. Frasch, P. M. Henson, K. Nagaosa, M. B. Fessler, N. Borregaard, and D. L. Bratton
Phospholipid Flip-Flop and Phospholipid Scramblase 1 (PLSCR1) Co-localize to Uropod Rafts in Formylated Met-Leu-Phe-stimulated Neutrophils
J. Biol. Chem., April 23, 2004; 279(17): 17625 - 17633.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
K. Okuma, K. P. Dalton, L. Buonocore, E. Ramsburg, and J. K. Rose
Development of a Novel Surrogate Virus for Human T-Cell Leukemia Virus Type 1: Inhibition of Infection by Osteoprotegerin
J. Virol., August 1, 2003; 77(15): 8562 - 8569.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Yang, M. Borset, J. K. Langford, and R. D. Sanderson
Heparan Sulfate Regulates Targeting of Syndecan-1 to a Functional Domain on the Cell Surface
J. Biol. Chem., April 4, 2003; 278(15): 12888 - 12893.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
M. GOTTE
Syndecans in inflammation
FASEB J, April 1, 2003; 17(6): 575 - 591.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Standal, C. Seidel, O. Hjertner, T. Plesner, R. D. Sanderson, A. Waage, M. Borset, and A. Sundan
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells
Blood, September 26, 2002; 100(8): 3002 - 3007.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Y. Pumphrey, A. M. Theus, S. Li, R. S. Parrish, and R. D. Sanderson
Neoglycans, Carbodiimide-modified Glycosaminoglycans: A New Class of Anticancer Agents That Inhibit Cancer Cell Proliferation and Induce Apoptosis
Cancer Res., July 1, 2002; 62(13): 3722 - 3728.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
C. Dominguez-Jimenez, D. Sancho, M. Nieto, M. C. Montoya, O. Barreiro, F. Sanchez-Madrid, and R. Gonzalez-Amaro
Effect of pentoxifylline on polarization and migration of human leukocytes
J. Leukoc. Biol., April 1, 2002; 71(4): 588 - 596.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. W. B. Derksen, R. M. J. Keehnen, L. M. Evers, M. H. J. van Oers, M. Spaargaren, and S. T. Pals
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma
Blood, February 15, 2002; 99(4): 1405 - 1410.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Millan, M. C. Montoya, D. Sancho, F. Sanchez-Madrid, and M. A. Alonso
Lipid rafts mediate biosynthetic transport to the T lymphocyte uropod subdomain and are necessary for uropod integrity and function
Blood, February 1, 2002; 99(3): 978 - 984.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Q. Chen, B. Gong, A. S. Mahmoud-Ahmed, A. Zhou, E. D. Hsi, M. Hussein, and A. Almasan
Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma
Blood, October 1, 2001; 98(7): 2183 - 2192.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Seidel, O. Hjertner, N. Abildgaard, L. Heickendorff, M. Hjorth, J. Westin, J. L. Nielsen, H. Hjorth-Hansen, A. Waage, A. Sundan, et al.
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease
Blood, October 1, 2001; 98(7): 2269 - 2271.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. N. Pearse, E. M. Sordillo, S. Yaccoby, B. R. Wong, D. F. Liau, N. Colman, J. Michaeli, J. Epstein, and Y. Choi
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
PNAS, September 13, 2001; (2001) 201394498.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. N. Pearse, E. M. Sordillo, S. Yaccoby, B. R. Wong, D. F. Liau, N. Colman, J. Michaeli, J. Epstein, and Y. Choi
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
PNAS, September 25, 2001; 98(20): 11581 - 11586.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020